In the RESPONSE trial, seladelpar 10 mg once daily significantly reduced itch severity at 6 months compared with placebo (LS ...

Linerixibat decreased serum interleukin-31 levels in patients with primary biliary in cholangitis after 24 weeks, which may ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced new long-term data reinforcing the safety and efficacy profile of ...

A pooled analysis of two phase 3 clinical trials shows that the first-in-class drug improves itching and itching-related ...

Gilead’s Livdelzi demonstrates sustained efficacy in PBC, offering ALP reduction, itch relief and potential to slow disease progression: Foster City, California Monday, November ...

New safety and efficacy data for primary biliary cholangitis (PBC) treatment Livdelzi (seladelpar) was presented today at The Liver Meeting, hosted by the American Association for the Study of Liver ...

The expansion of the cholestatic pruritus market across the US will be driven by the introduction of innovative therapies, ...

Three-year data from ongoing open-label study supported safety and effectiveness of seladelpar in patients with primary biliary cholangitis.

Gilead (GILD) announced new long-term data reinforcing the safety and efficacy profile of Livdelzi for people living with primary biliary ...

This year’s scientific meeting had the highest patient attendance in AASLD history. The patients' message: stigma delays ...

In medicine, treatment goals set by physicians might differ from patient priorities. Although normalisation of laboratory parameters is a target supported by outcomes data, patient perspectives ...

Gilead's Trodelvy missed a key goal in breast cancer, while Livdelzi showed durable efficacy and safety in long-term liver ...